Kyle Bass’ suits against pharmaceutical companies are starting to gain some traction at the PTAB.
The hedge fund manager gained renown last year for short-selling pharmas and then challenging their patents with petitions for inter partes review, often causing temporary drops in the companies’ stock prices. But the petitions didn’t have much success at the Patent Trial and Appeal Board (PTAB).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
